Once-daily enoxaparin in pediatric thromboembolism: A dose finding and pharmacodynamics/pharmacokinetics study [8]

Journal of Thrombosis and Haemostasis

Volumn 5, Issue 9, 2007, Pages 1985-1987

  O'Brien, Sarah H ^a,c   Lee, H ^b   Ritchey, A K ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; ENOXAPARIN; FIBRINOLYTIC AGENT; HEPARIN;

ADOLESCENT; ANTICOAGULATION; AREA UNDER THE CURVE; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; DRUG CLEARANCE; DRUG DISTRIBUTION; FOLLOW UP; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INFANT; INJECTION SITE REACTION; LETTER; LUNG HEMORRHAGE; PATIENT MONITORING; PRIORITY JOURNAL; RECURRENT DISEASE; THROMBOEMBOLISM;

ADOLESCENT; ANTICOAGULANTS; AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; ENOXAPARIN; HUMANS; INFANT; THROMBOEMBOLISM;

EID: 34548085625     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02624.x     Document Type: Letter

References (15)

1. Monagle P, Chan A, Massicotte P, Chalmers E, Michelson AD. Antithrombotic therapy in children: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 645S-87S.
2. Merli G, Spiro TE, Olsson CG, Abildgaard U, Davidson BL, Eldor A, Elias D, Grigg A, Musset D, Rodgers GM, Trowbridge AA, Yusen RD, Zawilska K. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 2001; 134: 191-202.
3. -1. Thromb Res 1992; 1: 167 (Abstract).
4. Parent F, Collignon F, Darne B, Ozoux M-L, Saliba E, Simonneau G. Treatment of venous thrombo-embolism with a daily subcutaneous injection of enoxaparin: Preliminary results of a pharmacokinetic study. Thromb Haemost 1993; 69 (Suppl.): 860 (Abstract).
5. van Dongen CJ, MacGillavry MR, Prins MH. Once versus twice daily LMWH for the initial treatment of venous thromboembolism. Cochrane Database Syst Rev 2005; 3: CD003074.
6. Gonzalez-Fajardo JA, Arreba E, Castrodeza J, Perez JL, Fernandez L, Agundez I, Mateo AM, Carrera S, Gutierrez V, Vaquero C. Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis. J Vasc Surg 1999; 30: 283-92.
7. Kucher N, Quiroz R, McKean S, Sasahara AA, Goldhaber SZ. Extended enoxaparin monotherapy for acute symptomatic pulmonary embolism. Vasc Med 2005; 10: 251-6.
8. Veiga F, Escriba A, Maluenda MP, Lopez Rubio M, Margalet I, Lezana A, Gallego J, Ribera JM. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: A randomized trial. Thromb Haemost 2000; 84: 559-64.
9. Dager WE, White RH. Low-molecular-weight heparin-induced thrombocytopenia in a child. Ann Pharmacother 2004; 38: 247-50.
10. Schobess R, During C, Bidlingmaier C, Heinecke A, Merkel N, Nowak-Gottl U. Long-term safety and efficacy data on childhood venous thrombosis treated with a low molecular weight heparin: An open-label pilot study of once-daily versus twice-daily enoxaparin administration. Haematologica 2006; 91: 1701-4.
11. Manco-Johnson MJ. How I treat venous thrombosis in children. Blood 2006; 107: 21-9.
12. Laposata M, Green D, van Cott EM, Barrowcliffe TW, Goodnight SH, Sosolik RC. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: The clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med 1998; 122: 799-807.
13. Andrew M, deVeber G. Pediatric Thromboembolism and Stroke Protocols. Hamilton, Ontario: B.C. Decker Inc., 1997.
14. Sanderink GJ, Le Liboux A, Jariwala N, Harding N, Ozoux ML, Shukla U, Montay G, Boutouyrie B, Miro A. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther 2002; 72: 308-18.
15. George-Phillips KL, Bungard TJ. Use of low-molecular-weight heparin to bridge therapy in obese patients and in patients with renal dysfunction. Pharmacotherapy 2006; 26: 1479-90.